ACRV (Acrivon Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ACRV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Michaela Levin | Chief Business Officer | A | — | — |
| 2026-08-27 | Kristina Masson | EVP - Business Operations | Sell | — | — |
| 2026-08-20 | Eric Devroe | Chief Operating Officer | Sell | — | — |
| 2026-08-20 | Katharine Peterson | Chief Accounting Officer | Sell | — | — |
| 2026-08-20 | Mary Miller | Chief Legal Officer | Sell | — | — |
| 2026-08-20 | Kristina Masson | EVP - Business Operations | Sell | — | — |
| 2026-08-20 | Erick Gamelin | Chief Development Officer | Sell | — | — |
| 2026-08-06 | Adam D. Levy | Chief Financial Officer | Sell | — | — |
| 2026-08-06 | Adam D. Levy | Chief Financial Officer | Sell | — | — |
| 2026-07-23 | Mary Miller | Chief Legal Officer | Sell | — | — |
| 2026-06-22 | CHARLES M BAUM | Director | A | — | — |
| 2026-06-22 | Sharon Shacham | Director | A | — | — |
| 2026-06-22 | Derek DiRocco | Director | A | — | — |
| 2026-06-22 | Santhosh Palani | Director | A | — | — |
| 2026-06-22 | MICHAEL JOHN TOMSICEK | Director | A | — | — |
| 2026-06-22 | Rajeev M. Shah | Director | A | — | — |
| 2026-06-22 | Ivana Magovcevic-Liebisch | Director | A | — | — |
| 2026-05-26 | Peter Blume-Jensen | President and CEO | F | — | — |
| 2026-05-20 | Katharine Peterson | Chief Accounting Officer | A | — | — |
| 2026-05-20 | Eric Devroe | Chief Operating Officer | A | — | — |
| 2026-05-20 | Mary Miller | Chief Legal Officer | A | — | — |
| 2026-05-20 | CHARLES M BAUM | Director | A | — | — |
| 2026-05-20 | Ivana Magovcevic-Liebisch | Director | A | — | — |
| 2026-05-20 | Sharon Shacham | Director | A | — | — |
| 2026-05-20 | Adam D. Levy | Chief Financial Officer | A | — | — |
| 2026-05-20 | Santhosh Palani | Director | A | — | — |
| 2026-05-20 | Derek DiRocco | Director | A | — | — |
| 2026-05-20 | Kristina Masson | EVP - Business Operations | A | — | — |
| 2026-05-20 | MICHAEL JOHN TOMSICEK | Director | A | — | — |
| 2026-05-20 | Mansoor Raza Mirza | Chief Medical Officer | A | — | — |
| 2026-05-20 | Rajeev M. Shah | Director | A | — | — |
| 2026-05-20 | Erick Gamelin | Chief Development Officer | A | — | — |
| 2026-05-18 | Erick Gamelin | Chief Development Officer | F | — | — |
| 2026-05-18 | Katharine Peterson | Chief Accounting Officer | F | — | — |
| 2026-05-18 | Mary Miller | Chief Legal Officer | F | — | — |
| 2026-05-18 | Eric Devroe | Chief Operating Officer | F | — | — |
| 2026-05-18 | Kristina Masson | EVP - Business Operations | F | — | — |
| 2026-04-23 | RA Capital Healthcare Fund LP | Director | A | — | — |
| 2026-04-21 | Mary Miller | Chief Legal Officer | F | — | — |
| 2026-03-03 | Mary Miller | Chief Legal Officer | A | — | — |
| 2026-03-03 | Katharine Peterson | Chief Accounting Officer | A | — | — |
| 2026-03-03 | Eric Devroe | Chief Operating Officer | A | — | — |
| 2026-03-03 | Peter Blume-Jensen | President and CEO | A | — | — |
| 2026-03-03 | Erick Gamelin | Chief Development Officer | A | — | — |
| 2026-03-03 | Mansoor Raza Mirza | Chief Medical Officer | A | — | — |
| 2026-03-03 | Adam D. Levy | Chief Financial Officer | A | — | — |
| 2026-02-24 | Peter Blume-Jensen | President and CEO | F | — | — |
| 2026-02-18 | Eric Devroe | Chief Operating Officer | F | — | — |
| 2026-02-18 | Katharine Peterson | Chief Accounting Officer | F | — | — |
| 2026-02-18 | Mary Miller | Chief Legal Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 7,914,206 | — |
| — | 10%+ Owner | 3,856,597 | — |
| — | 10%+ Owner | 3,848,648 | — |
| — | 10%+ Owner | 3,848,632 | — |
| — | 10%+ Owner | 3,104,139 | — |
| — | President and CEO | 2,631,660 | — |
| — | EVP - Business Operations | 2,615,911 | — |
| — | 10%+ Owner | 888,130 | — |
| — | Director | 426,302 | — |
| — | Chief Operating Officer | 146,349 | — |
| — | Chief Legal Officer | 82,009 | — |
| — | Chief Financial Officer | 66,008 | — |
| — | Chief Development Officer | 52,592 | — |
| — | Chief Medical Officer | 38,817 | — |
| — | Chief Business Officer | 30,000 | — |
| — | Chief Financial Officer | 26,088 | — |
| — | Chief Accounting Officer | 18,033 | — |
| — | Director | 9,366 | — |
| — | Director | 9,366 | — |
| — | Director | 9,366 | — |
| — | Director | 9,366 | — |
| — | Director | 9,366 | — |
| — | Director | 9,366 | — |
| — | Director | 9,366 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACRV quote page; the site-wide leaderboard is on the insider transactions hub.